Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

詳細情報 詳細情報について

• CRID

  1363951793714688384

• DOI

  10.1016/s1470-2045(11)70184-x

• ISSN

  14702045

  http://id.crossref.org/issn/14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S147020451170184X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S147020451170184X?httpAccept=text/plain

• データソース種別

  • Crossref